TSVT | 2seventy bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.29 - 4.50
52 Week Range	1.5350 - 6.40
Beta	1.69
Implied Volatility	426.49%
IV Rank	43.86%
Day's Volume	137,096
Average Volume	422,229
Shares Outstanding	51,497,930
Market Cap	226,590,892
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-11-03

Valuation
Profitability
Growth
Health
P/E Ratio	-1.44
Forward P/E Ratio	N/A
EPS	-3.06
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	274
Country	USA
Website	TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

TSVT's peers: PBYI, ICPT, IOVA, SRPT, DAWN, INZY, ZNTL, SNDX, PTGX, THRX, CGEM, MRSN, RLAY, RCUS, STOK, KZR, PHAT, REPL, KDNY, DICE, PLRX, CRNX, ASND, VERU, VNDA, XBIT

*Chart delayed

Analyzing fundamentals for TSVT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see TSVT Fundamentals page.

Watching at TSVT technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on TSVT Technicals page.